KR100385529B1 - 신규 디하이드록시헥산산 유도체 - Google Patents

신규 디하이드록시헥산산 유도체 Download PDF

Info

Publication number
KR100385529B1
KR100385529B1 KR10-2000-7008561A KR20007008561A KR100385529B1 KR 100385529 B1 KR100385529 B1 KR 100385529B1 KR 20007008561 A KR20007008561 A KR 20007008561A KR 100385529 B1 KR100385529 B1 KR 100385529B1
Authority
KR
South Korea
Prior art keywords
compounds
methyl
carboxylic acid
dihydroxy
octyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2000-7008561A
Other languages
English (en)
Korean (ko)
Other versions
KR20010040684A (ko
Inventor
카트존찰스
브라운매튜프랭크
포쓰크리스토퍼스탠리
Original Assignee
화이자 프로덕츠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 프로덕츠 인코포레이티드 filed Critical 화이자 프로덕츠 인코포레이티드
Publication of KR20010040684A publication Critical patent/KR20010040684A/ko
Application granted granted Critical
Publication of KR100385529B1 publication Critical patent/KR100385529B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
KR10-2000-7008561A 1998-02-05 1999-01-18 신규 디하이드록시헥산산 유도체 Expired - Fee Related KR100385529B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05
US60/073,801 1998-02-05

Publications (2)

Publication Number Publication Date
KR20010040684A KR20010040684A (ko) 2001-05-15
KR100385529B1 true KR100385529B1 (ko) 2003-05-27

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7008561A Expired - Fee Related KR100385529B1 (ko) 1998-02-05 1999-01-18 신규 디하이드록시헥산산 유도체

Country Status (36)

Country Link
EP (1) EP1051405B1 (https=)
JP (1) JP3693916B2 (https=)
KR (1) KR100385529B1 (https=)
CN (1) CN1177834C (https=)
AP (1) AP992A (https=)
AR (1) AR016175A1 (https=)
AT (1) ATE337307T1 (https=)
AU (1) AU752407B2 (https=)
BG (1) BG104726A (https=)
BR (1) BR9907655A (https=)
CA (1) CA2320388C (https=)
DE (1) DE69932920T2 (https=)
DZ (1) DZ2717A1 (https=)
EA (1) EA003137B1 (https=)
ES (1) ES2268847T3 (https=)
GT (1) GT199900011A (https=)
HR (1) HRP20000529B1 (https=)
HU (1) HUP0100832A3 (https=)
IL (1) IL137330A0 (https=)
IS (1) IS5562A (https=)
MA (1) MA26603A1 (https=)
MY (1) MY133125A (https=)
NO (1) NO20003965D0 (https=)
NZ (1) NZ505724A (https=)
OA (1) OA11448A (https=)
PA (1) PA8467301A1 (https=)
PE (1) PE20000243A1 (https=)
PL (1) PL342817A1 (https=)
SK (1) SK11262000A3 (https=)
TN (1) TNSN99013A1 (https=)
TR (1) TR200002248T2 (https=)
TW (1) TW470744B (https=)
UA (1) UA57824C2 (https=)
WO (1) WO1999040061A2 (https=)
YU (1) YU47100A (https=)
ZA (1) ZA99873B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360672A1 (en) * 1999-01-29 2000-08-03 Wayne W. Hancock Methods for preventing graft rejection and ischemia-reperfusion injury
PL205059B1 (pl) * 1999-08-20 2010-03-31 Dow Agrosciences Llc Heterocykliczny amid aromatyczny, jego kompozycja grzybobójcza oraz sposób zwalczania lub zapobiegania zakażeniom grzybami
EA200401099A1 (ru) 2000-02-04 2005-02-24 Пфайзер Продактс Инк. Производные гетероциклического амида
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
US6740636B2 (en) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
OA12625A (en) 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EP1506182A1 (en) * 2002-05-14 2005-02-16 Pfizer Products Inc. Methods for the manufacture of dihydro-furan-2-one derivatives
BR0309930A (pt) 2002-05-14 2005-02-09 Pfizer Prod Inc Derivados do ácido dihidroxihexanóico, seus intermediários e métodos de produção
WO2004014875A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide
EP1530457B1 (en) 2002-08-12 2009-09-09 Bend Research, Inc. Pharmaceutical compositions of drugs in semi-ordered form and polymers
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
DK0708085T3 (da) * 1994-10-19 2002-11-11 Novartis Ag Antivirale ethere af aspartatproteasesubstrat-isostere
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
MA26603A1 (fr) 2004-12-20
WO1999040061A3 (en) 1999-10-21
NO20003965L (https=) 2000-10-03
DZ2717A1 (fr) 2003-09-01
HUP0100832A2 (hu) 2002-02-28
JP3693916B2 (ja) 2005-09-14
ATE337307T1 (de) 2006-09-15
YU47100A (sh) 2002-11-15
BR9907655A (pt) 2000-10-24
AP9901457A0 (en) 1999-03-31
TNSN99013A1 (fr) 2005-11-10
AR016175A1 (es) 2001-06-20
SK11262000A3 (sk) 2001-01-18
ES2268847T3 (es) 2007-03-16
HUP0100832A3 (en) 2002-03-28
ZA99873B (en) 2000-08-04
DE69932920T2 (de) 2007-02-08
EA003137B1 (ru) 2003-02-27
DE69932920D1 (de) 2006-10-05
HRP20000529A2 (en) 2001-08-31
CN1177834C (zh) 2004-12-01
EP1051405A2 (en) 2000-11-15
CN1290255A (zh) 2001-04-04
CA2320388A1 (en) 1999-08-12
JP2002502839A (ja) 2002-01-29
PL342817A1 (en) 2001-07-02
AU752407B2 (en) 2002-09-19
IL137330A0 (en) 2001-07-24
KR20010040684A (ko) 2001-05-15
HRP20000529B1 (en) 2004-12-31
PA8467301A1 (es) 2000-05-24
IS5562A (is) 2000-07-14
GT199900011A (es) 2000-07-20
CA2320388C (en) 2005-05-03
TW470744B (en) 2002-01-01
NZ505724A (en) 2003-02-28
WO1999040061A2 (en) 1999-08-12
PE20000243A1 (es) 2000-04-07
NO20003965D0 (no) 2000-08-04
MY133125A (en) 2007-10-31
UA57824C2 (uk) 2003-07-15
EA200000741A1 (ru) 2001-02-26
AP992A (en) 2001-08-06
OA11448A (en) 2003-11-18
HK1034969A1 (en) 2001-11-09
EP1051405B1 (en) 2006-08-23
AU1778999A (en) 1999-08-23
TR200002248T2 (tr) 2000-12-21
BG104726A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
KR100385529B1 (ko) 신규 디하이드록시헥산산 유도체
EP0966443B1 (en) Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
US7053057B2 (en) Caspase inhibitors and uses thereof
WO2008134228A1 (en) Benzoxazole compounds
US6673801B1 (en) Dihydroxyhexanoic acid derivatives
NZ523610A (en) A method of treating inflammatory conditions in a non-human mammal comprising administration of dihydroxyhexanoic acid derivatives
MXPA00007690A (en) Novel dihydroxyhexanoic acid derivatives
CZ20002760A3 (cs) Nové deriváty dihydroxyhexanové kyseliny a farmaceutický prostředek, který je obsahuje
US20040087571A1 (en) Methods of using CCR1 antagonists as immunomodulatory agents
HK1034969B (en) Dihydroxyhexanoic acid derivatives
US6858744B2 (en) Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
CZ9902904A3 (cs) Deriváty amidů heteroarylhexanových kyselin, farmaceutické kompozice na jejich bázi a způsoby léčení nebo prevence
KR20050046005A (ko) 퀴녹살린-2-카르복실산[4-카르바모일-1-(3-플루오로벤질)-2,7-디히드록시-7-메틸-옥틸]-아미드의 결정형

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060516

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060516